As of the last check in current trading, shares of Guardion Health Sciences Inc. (Nasdaq: GHSI) are up 44.20 percent at $0.20 after positive clinical results were released. GHSI stock closed the last session at $0.14 and fluctuated between $0.136 and $0.143.
What are the clinical results that GHSI has shared with you?
Guardion Health (GHSI) announced interim results of a four-week clinical study to determine the effectiveness of Viactiv Omega Boost Gel Bites in increasing levels of Omega-3 fatty acids in red blood cells. As a total body support supplement, these 1,200 mg Omega-3 gel bites contain both DHA and EPA, thereby providing an overall health boost, which includes cardiovascular health, brain health, immunity, and eye health.
In addition to providing the potency of large, hard-to-swallow soft gels, the new gel bite dose form provides the taste and potency of gummies with even more Omega-3 than the leading omega-3 gum. There is no sugar in the gel bite delivery and there is no fishy aftertaste in the gel bite.
What has GHSI observed?
Despite Viactiv Omega Boost being positioned at a more premium price point, it is clearly a better value for its consumers because it is proven to work. Guardion Health (GHSI) reported that interim clinical results showed a 51% improvement in Omega-3 levels in just 4 weeks. It matters how much high-quality Omega-3s are contained in a supplement, and this product demonstrates GHSI’s continued commitment to delivering science-based, clinically-supported supplements that can make a real difference to the health of its customers.
